<DOC>
	<DOC>NCT01876745</DOC>
	<brief_summary>This study is conducted in Asia. The aim of the study is to evaluate the safety and efficacy of NovoSeven® (activated recombinant factor VII, eptacog alfa (activated)) during bleeding episodes and for the prevention of bleeding during surgery/delivery in patients with Glanzmann's thrombasthenia (GT)/Glanzmann's disease.</brief_summary>
	<brief_title>A Study to Evaluate Safety and Efficacy of NovoSeven® in Patients With Glanzmann's Thrombasthenia in Japan</brief_title>
	<detailed_description />
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<mesh_term>Thrombasthenia</mesh_term>
	<criteria>Informed consent obtained before any studyrelated activities (Study related activity are any procedure related to recording of data according to the protocol). Alltreated patients in the registration period Known or suspected allergy to study product(s) or related products Septicaemia (especially, septicaemia followed severely infected patients caused by gramnegative bacteria [The risk of DIC (disseminated intravascular coagulation) caused by endotoxemia could not denied] Patients with a history of hypersensitivity to any of the product components</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>